A multicenter, prospective, non-interventional cohort study to evaluate the safety and treatment pattern of sodium zirconium cyclosilicate for hyperkalaemia management in real world practice in China

Trial Identifier:	D9483R00001
Sponsor:	AstraZeneca
NCTID::	NCT05271266
Start Date:	March 2022
Primary Completion Date:	January 2024
Study Completion Date:	January 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Shanghai, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.